Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in hospitalized HFrEF patients with low blood pressure
ChiCTR2600125254Phase 4Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat arm with Placebo arm (2 arms). Primary endpoints: Change in LVEF at day 90 and Change in 6-minute walk distance at day 90. Planned start May 2026; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2600125254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125254.